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Abstract: 
 
Background and Purpose: Recurrent ischemic events are common in children with arterial 
ischemic stroke (AIS), and put patients at risk for further neurological impairment. This study 
sought to identify rates and risk factors for recurrent AIS or transient ischemic attack (TIA) in a 
cohort of children seen after index AIS and uniformly investigated and managed using 
contemporary clinical guidelines. 
 
Methods: Case note and radiology review of children >28 days and <18 years who presented to 
Great Ormond Street Hospital (GOSH) from 2005 to 2015 with index AIS.  Demographic 
characteristics, medical history, index AIS features, radiological findings, and neurological 
outcome were examined. Recurrence was identified from clinical records and coded as AIS (if 
there was associated new cerebral infarction) or TIA. 
 
Results: Eighty-four children (43 girls, median age at index AIS = 4.1 years) were identified.  
Cumulative AIS recurrence was 5% at 1 month, 10% at 3 months, 12% at 6 months, 12% at 12 
months, and 15% at 60 months after index event. Factors that independently predicted AIS 
recurrence were referral to GOSH from outside the catchment area, a prior relevant diagnosis, 
bilateral arteriopathy and AIS CASCADE category 3.a. or 3.b. Multiple infarcts and evidence of 
mature, as well as acute, infarcts on first brain imaging, while independently associated with AIS 
recurrence were also associated with bilateral arteriopathy.  Only CASCADE categories 3.a. and 
3.b. (bilateral cerebral arteriopathy with or without collaterals) remained significant in 
multivariate analysis.  AIS recurrence was not associated with poor neurological outcome. 
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Conclusions: AIS recurrence remains a significant problem despite the wide use of 
antithrombotic medications.  AIS subtypes should direct clinicians and future trials to use 
stratified management strategies and durations of treatment.  Bilateral cerebral arteriopathies are 
especially sinister and consensus criteria should be developed to improve consistency of 
management. 
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Introduction 
Arterial ischemic stroke (AIS) is an important cause of childhood morbidity and mortality.[1-3] 
Treatment to limit acute brain injury remains limited and clinical effort is focused on preventing 
recurrence and accrual of additional injury. Although several childhood stroke clinical guidelines 
have been published,[4, 5] most are based on expert consensus rather than trial evidence.  The 
impact of these in a clinical population has not been examined. Estimates of recurrence risk vary 
widely[6, 7] and design and execution of trials of secondary prevention are a major current focus 
of research in pediatric AIS.[8] 
 
The aims of this study were to describe rates of and risk factors for recurrence in a recent single 
centre cohort of children with AIS, investigated and managed in a uniform manner according to 
contemporary clinical guidelines.[4] 
 
Methods 
The data that support the findings of this study are available from the corresponding author upon 
reasonable request.  
 
Arterial ischemic stroke was defined as acute focal neurological deficit with radiological 
evidence of cerebral infarction in a corresponding arterial distribution. Children aged >28 days 
and <18 years presenting to Great Ormond Street Hospital (GOSH) with index AIS between 
2005 – 2015 were included. GOSH serves as the tertiary paediatric neurology centre for North 
London and does not have an emergency department; all patients would have been initially 
assessed in one of the feeder general paediatric units. Those with transient ischemic attack (TIA) 
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presentation (without brain infarction), or those only referred after recurrence, were excluded. 
Over this period, patients were investigated and managed in compliance with the Royal College 
of Physicians (RCP) Childhood Stroke Guidelines 2004.[4] This review of existing clinical and 
radiological data was categorized as clinical audit by the hospital, without requirement for ethical 
committee review. 
 
Case notes and brain imaging studies were reviewed retrospectively. All imaging studies had 
been acquired for clinical assessment and selected at clinician discretion. All patients had had 
brain magnetic resonance imaging (MRI) and angiography (MRA) of the cerebral and cervical 
arterial circulation at presentation and follow-up, that had been clinically reported by a 
consultant neuroradiologist at GOSH. Although some patients may have had other imaging 
studies (head computed tomography or digital subtraction angiography) during clinical 
assessment, only the MRI/A were assessed here.  
 
Clinical, laboratory, and radiological parameters recorded are summarized in table 1. These were 
selected following review of the literature, to examine factors previously implicated in index or 
recurrent AIS. The category “relevant prior diagnosis” included miscellaneous co-existing 
conditions previously reported to be associated with childhood AIS (listed separately in table 1). 
Referring hospital was coded as either within or outside of the GOSH north London catchment 
area to assess for any influence of referral centre bias.  
 
Hemoglobin concentration (within two weeks) and coagulation profile were coded as either 
normal or abnormal at index AIS. Coagulation profile included values for coagulation screen 
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(prothrombin time, activated partial thromboplastin time, fibrinogen), dilute Russell’s viper 
venom time, and levels of protein C, protein S, antithrombin, Factor VIII, and Factor XII. 
Follow-up data for patients with acute coagulation abnormalities were used to assess for definite 
thrombophilia. 
 
Initial brain MRI/A were reviewed as to site(s) of infarction (right/left/bilateral, anterior 
circulation/posterior circulation/both), multiplicity of infarcts (single/multiple), evidence of 
mature infarcts at the time of index event/scan (from previous clinically silent infarction), and 
arteriopathy location (right/left/bilateral carotid/vertebral circulation, anterior/posterior/both 
circulation). A patient with multiple infarcts within a single vessel territory was considered to 
have multiple infarcts.  
 
Follow-up brain MRI and MRA were reviewed to identify any change in brain appearance (new 
infarcts and/or extension of previous infarct(s) from index AIS) and evolution in arteriopathy 
categorised as progressive (longer segment involved of previously abnormal artery or 
involvement of new arteries)/reversible/stable. AIS subtype was categorised according to the 
CASCADE classification.[9]  
 
Recurrence was considered any cerebral ischemic event occurring after the index AIS, including 
further AIS (with new brain infarction), TIA (reversible event judged by treating clinician to be 
significant, without new infarcts) or clinically “silent” infarcts. Neurological outcome was scored 
from case notes using the Recurrence and Recovery Questionnaire[10] (RRQ) and dichotomized 
into “good” and “poor” categories as previously described.[2] 
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Survival analysis was used to find rates of first recurrence in the sample. Cases were censored at 
death or on the date of last documentation for patients without recurrence.  Kaplan-Meier 
survival curves were used to visualize the proportion of patients who remained recurrence free. 
To investigate predictors of recurrence, hazard ratios and 95% confidence intervals were found 
using univariate Cox regression; significant and clinically relevant factors were entered into a 
multivariable model. Chi-square tests were used to find associations between outcomes, 
recurrence, and bilateral disease, and between bilateral disease and infarct characteristics. These 
tests used an adjusted critical p-value found by dividing 0.05 by the number of comparisons 
made. All analyses were performed with SPSS version 24 (IBM Corporation, Armonk, NY). 
 
Results 
Eighty-four children (43 girls), were identified.  Sixty were referred from within the GOSH north 
London catchment area.  Median age at index AIS was 4.1 years (interquartile range (IQR): 2.4 – 
7.0 years), and patients were followed for a median of 2.4 years (IQR: 1.5 – 4.0 years). Data on 
medical history, acute investigations, and imaging studies at index AIS are summarised in table 
1.  
 
Nearly all patients (82/84) had received a medical intervention after index AIS, in accordance 
with the RCP clinical guidelines; the two who did not experienced recurrent AIS, and it was 
unclear from notes review why they were not initially treated.  Data on interventions after index 
AIS are summarised according to CASCADE classification in table 2. 
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Figure 1 shows survival curves for children with recurrent AIS and any clinical recurrence. For 
full details on recurrence risk at specific time points, see http://stroke.ahajournals.org. The 
median interval to AIS recurrence was 2.3 months; 77% of recurrent AIS occurred within the 
first 6 months after index AIS. AIS recurred in 10/17 children specifically with bilateral 
arteriopathy (CASCADE 3.a. n=10; 3.b. n=6; 4.a. n=1), all of which occurred within 12.5 
months of index event (figure 2). Two patients with no arteriopathy had another AIS; one of 
these patients had a cardiac condition and factor V Leiden mutation, the other had a cardiac 
condition and a relevant prior diagnosis (antiphospholipid antibodies). Of the 16 children with 
TIA recurrence, 5 also had recurrent AIS (CASCADE 3.a. n=1; 3.b. n=3; 6.a. n=1). The number 
of clinical recurrences (AIS and/or TIA) ranged from 1 – 11, with 12 patients experiencing 
multiple clinical recurrences. Seven children with more than one clinical recurrence were 
classified as CASCADE 3.a. or 3.b.  Bilateral disease was significantly associated with both 
multiple acute infarcts (p<0.001) and mature infarcts at index AIS (p<0.001) in chi-square 
analysis. 
 
Follow-up brain and cerebrovascular imaging studies were available for 78/84 children after a 
median of 2.0 years (IQR: 1.1 – 4.0 years).  Five children without follow-up imaging had not 
experienced any recurrence, and 1 further child was diagnosed with recurrent TIA but no 
recurrent AIS.  Hence, all 13 children with recurrent AIS were re-imaged during follow-up and 
showed either new infarction or an extension of a previous infarct.  No changes in brain imaging 
were seen in the 10 children with recurrent TIA only and follow-up scans, or in the 55 re-imaged 
children with no clinical recurrence. 
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Fifty-three of the 54 children with arteriopathies at presentation were re-imaged during follow-
up: 11 children showed arteriopathy progression (CASCADE 3.a. n=2; 3.b. n=5; 4.a. n=1; 6.b. 
n=3), while arteriopathy had improved in 14 and remained stable in 28. 
 
Thirty-five of 84 children had a poor neurological outcome on the RRQ. Of note, inspection of 
the raw RRQ scores showed that most patients were assigned a low level of impairment in most 
domains, with only a few scored as having a major functionally limiting impairment – however, 
on the RRQ assignment of anything other than a “no impairment” score in any domain allocates 
the child to the “poor” outcome group. Children with no or unilateral arteriopathy generally had 
good outcome, although these factors were not significantly associated with outcome. There was 
a significant association between bilateral arteriopathy and poor outcome (p=0.007); the risk of 
poor outcome was 71% for these children. Poor outcome was also more common among children 
with AIS recurrence but not significantly so (chi-square=2.5; p=0.11). 
 
In univariate Cox regression children referred to GOSH from hospitals outside the north London 
catchment area, a previous diagnosis known to be associated with AIS and bilateral cerebral 
arteriopathy were significantly more likely to experience recurrent AIS. With regard to AIS 
subtype, bilateral cerebral arteriopathy with (CASCADE 3.a.) and without collaterals (3.b.) 
significantly predicted recurrence.  Those with established, mature infarcts at the time of index 
clinical presentation, and those with multiple infarcts were also more likely to experience 
recurrence.  In contrast to previous studies, co-existence of multiple risk factors for index AIS 
and arteriopathy progression were not significantly predictive of recurrence[11, 12] (table 3). 
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Multivariate Cox regression, adjusted for age, also included data on referring hospital, prior 
diagnoses, and CASCADE classification. Infarct characteristics were not included because of 
their association with bilateral disease. Only CASCADE categories 3.a. (hazard ratio: 13.2 (95% 
CI 1.4 – 122.7); p=0.02) and 3.b. (HR: 25.3 (95% CI 2.6 – 243.8); p=0.005) remained predictive 
of recurrent AIS. 
 
Discussion 
In this contemporary group of uniformly managed children with AIS, AIS recurrence rate was 
12% within 6 months, and 15% within 5 years.  The 5-year cumulative risk of AIS and/or TIA 
was 29% (24/84 children), with 12 multiple recurrences. Imaging predictors of recurrent AIS 
were bilateral arteriopathy (CASCADE 3.a./3.b.), also associated with mature/multiple infarcts at 
presentation. 
 
Referral bias was evident, with more recurrences in children from outside the GOSH catchment 
area. Bias is also evident in other studies, with population-based cohorts having fewer patients 
with high risk diagnoses such as moyamoya.[6]  Other limitations here include retrospective and 
missing data, and limited power. The latter likely explains the fewer posterior 
circulation/cardioembolic categories compared with previous cohorts, though this may also relate 
to inconsistency of diagnostic definitions between studies. Whilst it is surprising that recurrence 
was not significantly associated with outcome, it is important to acknowledge limitations of the 
dichotomized RRQ outcomes used, namely that children with very minimal functional deficit 
could still be classified as poor outcome. The key finding here is that recurrence risk, and its 
trajectory, varies according to AIS subtype, a key point to consider in future trial design.   
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The recurrence rate of 15% compares with an 18% rate in an older GOSH cohort[13] of whom 
only 62% received prophylaxis. The impact of consensus-derived clinical guidelines and more 
use of anti-thrombotics on recurrence rate appears to be limited, although compliance cannot be 
guaranteed. The 2017 Royal College of Paediatrics and Child Health childhood stroke guidelines 
are largely similar to 2004 guidelines, so it seems unlikely these will materially alter recurrence 
rates.[14] Thus the need for more effective, and targeted, interventions is clear. 
 
A recent physician survey suggests that combined corticosteroid-antithrombotic treatment for 
focal cerebral arteriopathy (FCA) is the highest priority for interventional studies in childhood 
AIS.[8] However, in contrast to other groups, FCA patients did not have a high recurrence rate in 
our study, nor did we find progressive arteriopathy to predict recurrence.[7, 11, 15-18] Though 
these differences likely partially relate to power, they emphasise the importance of AIS 
subtyping in calculating risk and power for trials, that will need to be tailored to AIS subtype, 
rather than having a “one size fits all” design. 
 
A major difficulty in comparing data between studies is that radiological features of conditions 
with differing pathophysiology may be indistinguishable – for example FCA and primary angiitis 
of the central nervous system – that would be predicted to have differing natural histories. While 
CASCADE enables categorization of all AIS patients using predefined criteria, and is therefore a 
useful research tool, using radiology to subtype patients may falsely group patients with differing 
pathophysiology and natural history, again relevant to proposed interventions. 
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A population screening study in Japan suggested that moyamoya could be more benign than 
previously suggested, including asymptomatic cases.[19] However, it appears that outside Japan, 
bilateral arteriopathy in children with AIS is almost universally a malignant radiological 
signature and that within that group CASCADE 3.a. and 3.b. have differing disease 
trajectories.[20] Whilst a trial of surgical revascularization in these patients is unlikely to 
materialize, prospective multi-centre data collection and analysis could help refine decision 
making. In parallel, improving understanding of disease biology would contribute significantly 
to development of disease-targeted interventions, and would form a useful antecedent to clinical 
trials. 
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Figure legends:  
 
Figure 1. Whole cohort Kaplan-Meier survival curves for first recurrence.  Figure shows survival 
functions for both any ischemic recurrence (bold) and AIS recurrence groups. 
 
Figure 2. Kaplan-Meier survival curves for the patients with either bilateral (bold, solid), 
unilateral (thin, solid), or no arteriopathy (dotted). 
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Tables:  
Table 1. Clinical, Laboratory, and Radiological Investigations after Index AIS. FCA=Focal 
cerebral arteriopathy of childhood. *Includes genetic mutations and definite thrombophilia. 
Medical History N (% of cohort) 
Cardiac Conditions 18 (21%) 
Infections 33 (39%) 
    Chickenpox in past 12 months     17 
    Other infections in past 4 weeks     16 
Relevant Prior Diagnosis 18 (23%) 
    Trisomy 21     5 
    Sickle cell disease or sickle cell trait     2 
    Pulmonary hypertension     2 
    ACTA2 mutation     2 
    Meningitis     1 
    Neuroblastoma     1 
    Raynaud’s     1 
    Antiphospholipid antibodies     1 
    Hypothyroidism     1 
    Superior vena cava thrombus     1 
    Acute multi-focal placoid epitheliopathy     1 
Other Medical History  
    Head trauma in past 2 weeks     10 (12%) 
    Extracorporeal membrane oxygenation (ECMO)      2 (2%) 
 18 
Number of medical history risk factors*  
    None 19 (23%) 
    Single  32 (38%) 
    Multiple  33 (39%) 
Acute AIS Investigations (N Investigated) N Abnormal (%) 
Echocardiography (84) 13 (15%) 
Genetic Thrombophilia Mutations (66) 30 (45%) 
Acute Hemoglobin Concentration (69) 23 (33%) 
Acute Coagulation Profile (77) 20 (26%) 
    Definite thrombophilia at follow-up     2 
Brain Imaging N 
Number of infarcts  
    Single     54 
    Multiple     30 
Anterior circulation 77 
Posterior circulation 6 
Anterior and posterior circulation 1 
Uni/bilaterality of brain region affected  
    Left     34 
    Right     35 
    Bilateral     15 
Evidence of mature infarct at time of index AIS 18 
Arterial Imaging N 
 19 
No arteriopathy 30  
Anterior circulation 49 
Posterior circulation 3 
Anterior and posterior circulation 2 
Uni/bilaterality of arteriopathy  
    Unilateral     37 
    Bilateral     17 
CASCADE AIS subtype N (% of cohort) 
2.a. Unilateral FCA - Anterior circulation with collaterals  6 (7%) 
2.b. Unilateral FCA - Anterior circulation without collaterals  22 (26%) 
2.d. Unilateral FCA - Other 1 (1%) 
3.a. Bilateral cerebral arteriopathy – With collaterals 10 (12%) 
3.b. Bilateral cerebral arteriopathy – Without collaterals 6 (7%) 
4.a. Aortic/cervical arteriopathy - Dissection 3 (4%) 
5.a. Cardio-embolic – Definite 3 (4%) 
6.a. Other – undetermined etiology  25 (30%) 
6.b. Other – other  8 (10%) 
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Table 2. Interventions after index AIS by CASCADE classification.  
 2.a. 2.b. 2.d. 3.a. 3.b. 4.a. 5.a. 6.a. 6.b. Total 
Antiplatelet only 6 19 0 7 4 1 2 25 4 68 
Anticoagulation only 0 2 0 0 0 0 0 0 0 2 
Both antiplatelet and 
anticoagulation 
0 1 1 0 0 2 0 0 3 7 
Surgery and 
antithrombotic 
0 0 0 1* 0 0 1† 0 1‡ 3 
Blood transfusions 0 0 0 1 1 0 0 0 0 2 
No treatment 0 0 0 1 1 0 0 0 0 2 
*Revascularization surgery and antiplatelet. †: Mitral valve repair and antiplatelet. ‡: Fenestrated 
atrial septal defect closure and anticoagulation. 
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Table 3. Univariate Cox regression for AIS recurrence. 
Factor 
No AIS 
recurrence 
(n=71); n 
AIS 
recurrence 
(n=13); n 
HR (95% CI) P-value 
Age at index AIS 
(median) 
4.0 4.8 1.02 (0.91 – 1.14) 0.74 
Referring hospital 
outside catchment area 
(vs. within) 
16 8 4.31 (1.4 – 13.2) 0.01 
Number of AIS risk 
factors  
    
   None 17 2 Ref Ref 
   Single 26 6 1.84 (0.37 – 9.10) 0.46 
   Multiple 28 5 1.34 (0.26 – 7.0) 0.73 
Prior relevant diagnosis 
(vs. no prior diagnosis) 
11 7 5.0 (1.7 – 15.0) 0.004  
Progressive 
Arteriopathy (vs. stable 
or improved)* 
7 4 2.43 (0.71 – 8.32) 0.16 
Arteriopathy 
Uni/bilaterality 
    
   No arteriopathy 28 2 Ref Ref 
   Unilateral 36 1 0.39 (0.04 – 4.35) 0.45 
 22 
   Bilateral 7 10 11.6 (2.52 – 53.14) 0.002 
AIS Classification 
(CASCADE) 
    
   2.a. 6 0 0.00 (0.00) 0.99 
   2.b. 21 1 1.12 (0.07 – 17.91) 0.94 
   2.d. 1 0 0.00 (0.00) 0.99 
   3.a. 4 6 20.1 (2.4 – 167.9) 0.006 
   3.b. 2 4 24.1 (2.7 – 216.7) 0.004 
   4.a. 3 0 0.00 (0.00) 0.99 
   5.a. 3 0 0.00 (0.00) 0.99 
   6.a. 24 1 Ref Ref 
   6.b. 7 1 3.1 (0.19 – 49.5) 0.42 
Multiple infarcts at 
index AIS (vs. single) 
21 9 4.42 (1.36 – 14.38) 0.013 
Evidence of mature 
infarcts at index AIS 
11 7 5.16 (1.73 – 15.41) 0.003 
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Figure 1:  
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